San Diego-based aTyr Pharma named Frederic Chereau president and chief operating officer.
Chereau has more than 20 years of experience in bringing new rare disease products to market and has held key leadership positions at Shire and Genzyme.
Chereau “will further guide our global outreach and strategic partnerships to optimize value creation for aTyr as we translate Physiocrine biology into meaningful protein therapeutics for patients,” said John Mendlein, CEO and executive chairman of aTyr Pharma.
The company says its physiocrine therapeutics offer improved selectivity, efficacy and reduced side effects compared to many existing anti-inflammatory treatments. The company’s key programs currently focus on grave, rare immune disorders.
The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist.
SDBJ Staff Report